{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:41:49Z","timestamp":1793295709721,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Migraine is a frequent headache disorder with high disease burden. The aims of this study were to determine the administrative prevalence and incidence of migraine in Germany; and to elucidate disease characteristics, prescription patterns and the patient journey through the German healthcare system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective, observational study, adult patients with migraine (International Classification of Diseases, 10th revision, German modification G43) were identified in the anonymised German Company Sickness Fund database (CSFD) from 2008 through 2016. The administrative prevalence and incidence of migraine were calculated for the total CSFD study population and extrapolated to the German Statutory Health Insurance (SHI) population. Migraine subtypes, concurrent diagnoses, prescription patterns and visited healthcare professional groups were analysed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 243,471 patients with migraine were identified in the CSFD (2008\u20132016); 78.0% were female and 45.3% were aged 35\u201354\u2009years. The administrative prevalence of migraine, extrapolated to the SHI population, ranged between 2.89% in 2008 and 3.98% in 2016; administrative incidence ranged from 0.587% in 2009 to 0.267% in 2016, and varied between 0.399% and 0.442% during 2011 to 2015. Overall, 29.1% of patients received at least one prescription for any preventive medication listed in the German guideline. Only 7.9% received the same preventive medication for more than 1\u2009year, with 82.9% of these patients discontinuing the medication before study end. Regarding acute medications, 74.2% of prescriptions were for analgesics\/non-steroidal anti-inflammatory drugs and 21.2% were for triptans. General practitioners most commonly diagnosed and treated migraine in the CSFD population. Patients with prescriptions for two or more different preventive therapy classes had higher use of acute and emergency medications, and visited healthcare professionals and hospitals more frequently than patients with no prescriptions or prescriptions for only one preventive therapy class.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The administrative prevalence of migraine in this claims database suggests many patients with migraine did not seek medical care. Of those who did, fewer than one-third received preventive medication, with most patients having been prescribed only one such medication and few having continued treatment beyond 1\u2009year. These outcomes suggest there is scope for improvement in migraine management in Germany.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s10194-020-01154-x","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T12:03:44Z","timestamp":1594037024000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Administrative prevalence and incidence, characteristics and prescription patterns of patients with migraine in Germany: a retrospective claims data analysis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-532X","authenticated-orcid":false,"given":"Tatjana","family":"Roessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Zschocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Roehrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Friedrichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Friedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Katsarava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"1154_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd ed. Cephalalgia. 38:1\u2013211","DOI":"10.1177\/0333102417738202"},{"key":"1154_CR2","doi-asserted-by":"crossref","unstructured":"Lipton RB, Silberstein SD (2015) Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 55(Suppl 2):103\u2013122 quiz 123-126","DOI":"10.1111\/head.12505_2"},{"key":"1154_CR3","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/head.12038","volume":"53","author":"KR Merikangas","year":"2013","unstructured":"Merikangas KR (2013) Contributions of epidemiology to our understanding of migraine. Headache. 53:230\u2013246","journal-title":"Headache."},{"key":"1154_CR4","doi-asserted-by":"crossref","unstructured":"Diener HC, Solbach K, Holle D, Gaul C (2015) Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options. Clin Med (Lond). 15:344\u2013350","DOI":"10.7861\/clinmedicine.15-4-344"},{"key":"1154_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1129-2377-15-31","volume":"15","author":"TJ Steiner","year":"2014","unstructured":"Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lant\u00e9ri-Minet M et al (2014) The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain. 15:31","journal-title":"J Headache Pain."},{"key":"1154_CR6","doi-asserted-by":"publisher","first-page":"g1416","DOI":"10.1136\/bmj.g1416","volume":"348","author":"TJ Schwedt","year":"2014","unstructured":"Schwedt TJ (2014) Chronic migraine. BMJ. 348:g1416","journal-title":"BMJ."},{"key":"1154_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/head.13456","volume":"59","author":"American Headache Society","year":"2019","unstructured":"American Headache Society (2019) The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 59:1\u201318","journal-title":"Headache."},{"key":"1154_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2514183X18823377","volume":"3","author":"HC Diener","year":"2019","unstructured":"Diener HC, Holle-Lee D, N\u00e4gel S, Dresler T, Gaul C, G\u00f6bel H et al (2019) Treatment of migraine attacks and prevention of migraine: guidelines by the German migraine and headache society and the German Society of Neurology. CTN. 3:1\u201340","journal-title":"CTN."},{"key":"1154_CR9","unstructured":"Novartis Europharm Limited. Aimovig (erenumab). Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aimovig-epar-product-information_en.pdf. Accessed 25 Oct 2019"},{"key":"1154_CR10","unstructured":"Eli Lilly Nederland B.V. Emgality (galcanezumab). Summary of Product Characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emgality-epar-product-information_en.pdf. Accessed 25 Oct 2019"},{"key":"1154_CR11","unstructured":"European Medicines Agency. Ajovy (fremanezumab). Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ajovy. Accessed 25 Oct 2019"},{"key":"1154_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1526-4610.2008.01263.x","volume":"49","author":"A Radtke","year":"2009","unstructured":"Radtke A, Neuhauser H (2009) Prevalence and burden of headache and migraine in Germany. Headache. 49:79\u201389","journal-title":"Headache."},{"key":"1154_CR13","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10194-012-0425-x","volume":"13","author":"MS Yoon","year":"2012","unstructured":"Yoon MS, Katsarava Z, Obermann M, Fritsche G, Oezyurt M, Kaesewinkel K et al (2012) Prevalence of primary headaches in Germany: results of the German headache consortium study. J Headache Pain. 13:215\u2013223","journal-title":"J Headache Pain."},{"key":"1154_CR14","doi-asserted-by":"crossref","unstructured":"Woldeamanuel YW, Cowan RP (2017) Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 372:307\u2013315","DOI":"10.1016\/j.jns.2016.11.071"},{"key":"1154_CR15","doi-asserted-by":"crossref","unstructured":"Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ (2018) Poor medical care for people with migraine in Europe \u2013 evidence from the Eurolight study. J Headache Pain. 19:10","DOI":"10.1186\/s10194-018-0839-1"},{"key":"1154_CR16","doi-asserted-by":"crossref","unstructured":"Neubauer S, Kreis K, Klora M, Zeidler J (2017) Access, use, and challenges of claims data analyses in Germany. Eur J Health Econ. 18:533\u2013536","DOI":"10.1007\/s10198-016-0849-3"},{"key":"1154_CR17","unstructured":"Deutsches Institut f\u00fcr Medizinische Dokumentation und Information. Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme. 10. Revision. German Modification. Version 2019. Available at: https:\/\/www.dimdi.de\/static\/de\/klassifikationen\/icd\/icd-10-gm\/kode-suche\/htmlgm2019\/. Accessed 20 Apr 2019"},{"key":"1154_CR18","first-page":"108","volume":"20","author":"H Friedel","year":"2015","unstructured":"Friedel H, Clouth J, Br\u00fcck P, Nicolay C, Garal-Pantaler E, Moeser G et al (2015) A retrospective observational study of the epidemiology of advanced gastric cancer in Germany. An analysis of health insurance data from a central database. Gesundh \u00d6kon Qual Manag 20:108\u2013113","journal-title":"Gesundh \u00d6kon Qual Manag"},{"key":"1154_CR19","doi-asserted-by":"crossref","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF, AMPP Advisory Group (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 68:343\u2013349","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"1154_CR20","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/head.13202","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK (2017) A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache. 57:1532\u20131544","journal-title":"Headache."},{"key":"1154_CR21","doi-asserted-by":"crossref","unstructured":"Schneider-Ziebe A, May U (2019) The treatment of migraine patients with triptans \u2013 is there a need for further Rx-to-OTC switches? Gesundh \u00f6kon Qual manag. 25(01):15\u201323","DOI":"10.1055\/a-0836-2852"},{"key":"1154_CR22","doi-asserted-by":"crossref","unstructured":"Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB (2007) Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 47:355\u2013363","DOI":"10.1111\/j.1526-4610.2006.00631.x"},{"key":"1154_CR23","doi-asserted-by":"crossref","unstructured":"Obermann M, Katsarava Z (2008) Epidemiology of unilateral headaches. Expert Rev Neurother. 8:1313\u20131320","DOI":"10.1586\/14737175.8.9.1313"},{"key":"1154_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s10194-019-1034-8","volume":"20","author":"C Ziegeler","year":"2019","unstructured":"Ziegeler C, Brauns G, J\u00fcrgens TP, May A (2019) Shortcomings and missed potentials in the management of migraine patients - experiences from a specialized tertiary care center. J Headache Pain. 20:86","journal-title":"J Headache Pain."},{"key":"1154_CR25","doi-asserted-by":"crossref","unstructured":"Jacob L, Kostev K (2017) Prescription patterns and the cost of migraine treatments in German general and neurological practices. Pain Pract. 17:747\u2013752","DOI":"10.1111\/papr.12520"},{"key":"1154_CR26","first-page":"333102419835465","volume":"28","author":"M Bonafede","year":"2019","unstructured":"Bonafede M, Wilson K, Xue F (2019) Long-term treatment patterns of prophylactic and acute migraine medications and incidence of opioid-related adverse events in patients with migraine. Cephalalgia. 28:333102419835465","journal-title":"Cephalalgia."},{"key":"1154_CR27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 35:478\u2013488","journal-title":"Cephalalgia."},{"key":"1154_CR28","doi-asserted-by":"crossref","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 20:22\u201333","DOI":"10.18553\/jmcp.2014.20.1.22"},{"key":"1154_CR29","doi-asserted-by":"crossref","unstructured":"Vo P, Gao W, Zichlin ML, Fuqua E, Fadli E, Aguirre Vazquez M et al (2019) Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain. J Med Econ. 22:953\u2013959","DOI":"10.1080\/13696998.2019.1636051"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01154-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01154-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01154-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T09:34:39Z","timestamp":1723196079000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01154-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01154-x","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"5 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TR, JZ and AR are full-time employees and minor stock holders of Eli Lilly and Company. MF and HF are employees of Team Gesundheit, who were contracted by Eli Lilly to conduct the data analysis. ZK has received honoraria from Allergan, Novartis, Merck, TEVA and Lilly; none of these related to the submitted manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}